Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Phio Pharmaceuticals Corp. (PHIO : NSDQ)

• Company Description    Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation, is based in Marlborough, United States. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.09 Daily Weekly Monthly 20 Day Moving Average: 140,572 shares Shares Outstanding: 11.62 (millions) Market Capitalization: $12.66 (millions) Beta: 0.84 52 Week High: $3.48 52 Week Low: $0.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.38% -15.71% 12 Week 1.87% -5.83% Year To Date 3.81% -4.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 411 SWEDELAND ROAD SUITE 23-1080 - KING OF PRUSSIA,PA 19406 USA ph: 610-947-0251 fax: 508-767-3862 ir@phiopharma.com https://phiopharma.com

• General Corporate Information    Officers Robert J. Bitterman - Chief Executive Officer; Chairman and President Lisa C. Carson - Chief Financial Officer Patricia Bradford - Director Jonathan E. Freeman - Director Curtis A. Lockshin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 71880W501 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 11.62 Most Recent Split Date: 7.00 (0.11:1) Beta: 0.84 Market Capitalization: $12.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 17.07% vs. Previous Quarter: -126.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -77.34 12/31/25 - -66.59 09/30/25 - -86.38 ROA 03/31/26 - -70.87 12/31/25 - -60.26 09/30/25 - -75.77 Current Ratio 03/31/26 - 18.32 12/31/25 - 16.03 09/30/25 - 6.90 Quick Ratio 03/31/26 - 18.32 12/31/25 - 16.03 09/30/25 - 6.90 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.42 12/31/25 - 1.87 09/30/25 - 1.70 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©